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Neuromyelitis Optica (NMO) is an autoimmune disease with a higher prevalence in non‑European 
populations. Because the Mexican population resulted from the admixture between mainly Native 
American and European populations, we used genome‑wide microarray, HLA high‑resolution typing 
and AQP4 gene sequencing data to analyze genetic ancestry and to seek genetic variants conferring 
NMO susceptibility in admixed Mexican patients. A total of 164 Mexican NMO patients and 1,208 
controls were included. On average, NMO patients had a higher proportion of Native American 
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ancestry than controls (68.1% vs 58.6%; p = 5 × 10–6). GWAS identified a HLA region associated with 
NMO, led by rs9272219 (OR = 2.48, P = 8 × 10–10). Class II HLA alleles HLA‑DQB1*03:01, ‑DRB1*08:02, 
‑DRB1*16:02, ‑DRB1*14:06 and ‑DQB1*04:02 showed the most significant associations with NMO 
risk. Local ancestry estimates suggest that all the NMO‑associated alleles within the HLA region are 
of Native American origin. No novel or missense variants in the AQP4 gene were found in Mexican 
patients with NMO or multiple sclerosis. To our knowledge, this is the first study supporting the 
notion that Native American ancestry significantly contributes to NMO susceptibility in an admixed 
population, and is consistent with differences in NMO epidemiology in Mexico and Latin America.
Neuromyelitis optica (NMO) is a chronic autoimmune inflammatory and demyelinating disease of the central 
nervous system (CNS), which mainly affects the optic nerve and spinal cord. Although NMO was first described 
in the XIX century, it was considered a clinical variant of multiple sclerosis (MS) for  decades1,2. In 2004, the 
discovery of positive antiaquaporin-4 antibodies (AQP4-IgG) in serum of the majority of NMO patients led to 
significant progress in the clinical characterization of the disease, now acknowledged as a distinct entity with 
different immunological, clinical and epidemiological  features3,4.
Although it has been difficult to establish the actual prevalence of NMO, mainly because most reports are not 
comparable due to differences in study design, methodological approaches, and diagnostic criteria, worldwide 
NMO prevalence has been estimated between 0.51 and 4.4 cases per 100,000  inhabitants6,7. The prevalence and 
clinical manifestations of NMO vary among different ethnic groups, and several authors have stated that NMO 
is more frequent in non-European  populations8,9. Interestingly, the relative frequency of NMO (estimated as the 
ratio of NMO/(MS + NMO) cases) has been found to decrease gradually in South America from North (Ven-
ezuela) to South (Argentina). Because ethnicity also changes gradually from North to South in this region, with 
the proportion of European individuals being lower in Venezuela and higher in Argentina, the authors suggested 
that ethnic origin influences NMO frequency in Latin  America10. To date there are no population-based studies 
of the prevalence of NMO in Mexico, and there is a single study estimating NMO prevalence at 1.3 per 100,000 
inhabitants based on the NMO/(MS + NMO) relative frequency at a referral center in Mexico  City12.
Like many other autoimmune diseases, NMO is a multifactorial disorder that results from complex interac-
tions between genetic and environmental factors. Recent studies have reported associations of NMO with genetic 
variation in the Human Leukocyte Antigen (HLA) genome region in chromosome 6, particularly with class II 
alleles, showing ethnical and geographical differences: The DRB1*03:01 allele has been associated with NMO in 
 European13–16,  Brazilian17,18, Afro-Caribbean19 and Mexican  patients20; DRB1*16:02 in Southern Han  Chinese21, 
 Japanese22 and in Southern Brazilian  patients23; DQB1*04:02 in a European-ancestry  cohort13,24; and DRB1*04:05 
in Southern  Brazilians23. Moreover, candidate gene studies have reported associations with variation in non-HLA 
genes such as AQP4 and others involved in immune function (PD-1, IL-17, IL-7R, CD6 and CD58)24–28. Of the 
latter, only AQP4 gene variation has been analyzed in various populations by sequencing promoter and/or coding 
regions of the gene attempting to identify variants involved in the pathogenesis of NMO. However, the associa-
tion of AQP4 gene variation with NMO remains unclear, with inconsistent findings among  populations29–34.
Because the Mexican population of today resulted from a complex and ongoing admixture process involving 
mainly Native American and European genetic components, we hypothesized that Native American ancestry 
also contributes to NMO susceptibility in Mexican patients. We thus used genome-wide microarray data, HLA 
high-resolution typing and AQP4 gene sequencing data to explore genetic ancestry and to seek genetic variants 
conferring susceptibility to NMO in Mexican patients.
Results
The present study includes 164 patients with Neuromyelitis Optica (NMO) (79% female) and 1,208  controls 
(61% female).
Population admixture analysis. Reference Native American (NAT) and continental populations were 
used to generate a multidimensional scaling (MDS) plot. Figure 1. The left panel shows that components 1 and 
2 distinguish Africans (AFR) and Europeans (EUR) from NAT individuals. The average genome-wide propor-
tion of Native American ancestry was significantly higher in NMO patients than in controls (68.1% vs 58.6%; 
P = 5 × 10–6). Conversely, the average genome-wide proportion of European ancestry was lower in cases than 
in controls (28.3% vs 37.3%; P = 3 × 10–6), while African ancestry was similar in both groups (3.6% vs 4.1%; 
P = 0.143) (Fig. 1, right panel).
Genome‑wide association analysis. The genome-wide association analysis (GWAS) included 119 NMO 
cases and 1,208 controls. Figure 2 shows the Manhattan and Q-Q plots after adjusting for sex and two principal 
components. Six signals surpassed the genome-wide significance threshold (5 × 10–8), spanning a 173.1 kb region 
within the major histocompatibility complex (MHC) region. Two SNPs in perfect linkage disequilibrium (LD) 
(r2 = 1) showed the most significant associations under an additive model, rs9272219 (OR = 2.48, P = 8 × 10–10) and 
rs9273012 (OR = 2.49, P = 8 × 10–10), both within the HLA-DQA1 gene. As described in Table 1, two intergenic 
(rs1964995 and rs9271588) and two SNPs within the HLA-DRB9 gene (rs9368726 and rs9405108) were also 
significantly associated with NMO. LD estimations among these 6 SNPs ranged between 0.5 and 1 (0.5 < r2 < 1). 
In order to assess whether these associations are driven by a single SNP, we conditioned the analysis based on the 
rs9272219 genotype. No other associations maintained genome-wide significance in the conditioned analysis 
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(Supplementary Fig. 1). Table 1 also shows associations of these SNPs with NMO using the data of Estrada et al. 
 201816, available at https ://githu b.com/Bioge n-Inc/statg en (UTS/ACP data set). 
HLA analysis. Detailed HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 allele and haplotype fre-
quencies in study groups are described in Supplementary Tables 1–9. No HLA variant deviated from Hardy–
Weinberg equilibrium. Table  2 shows HLA alleles that differed significantly in frequency between NMO 
patients and controls. The most significantly NMO-associated HLA class II alleles (P < 0.01) were HLA-
DQB1*03:01 (P = 0.00008), -DRB1*08:02 (P = 0.0011), -DRB1*16:02 (P = 0.0014), -DRB1*14:06 (P = 0.00368) 
and -DQB1*04:02 (P = 0.00552), all associated with increased NMO risk, while -DQB1*03:02 (P = 0.00013) and 
-DQB1*02:02 (P = 0.00899) were associated with decreased NMO risk. Two-locus HLA haplotypes associated 
with NMO patients are listed in Table 3. The lead class II haplotype associated with increased NMO risk was 
HLA-DRB1*16:02-DQB1*03:01 (P = 0.0014), followed by HLA-DRB1*08:02-DQB1*04:02 (P = 0.00177) and 
Figure 1.  Global ancestry analysis. The left panel shows multidimensional scaling analysis of NMO patients and 
controls, with Europeans (CEU) and Africans (YRI) from the 1,000 Genomes projects, and unrelated central 
Native Mexican (NAT) individuals as reference populations. The right panel shows mean ancestry proportion 
estimated by ADMIXTURE assuming three parental populations (K = 3), in the entire study population, cases 
and controls.
Figure 2.  Genome-wide association analysis. Manhattan plot and Q–Q plot. P-values were obtained by logistic 
regression adjusting for sex and two principal components. Six signals surpassed the genome-wide significance 
threshold (5 × 10–8), spanning a 173.1 kb region in the major histocompatibility complex (MHC) region.
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-DRB1*14:06-DQB1*03:01 (P = 0.00368), while -DRB1*07:01-DQB1*02:02 (P = 0.00796) was associated with 
decreased NMO risk. No extended haplotypes differed significantly between patients and controls. 
Table 4 shows HLA class II alleles stratified by rs9272219 alleles (C/A). Interestingly, previously reported risk 
alleles HLA-DQB1*04:02 and -DRB1*16:02, as well as HLA-DQB1*03:01, -DRB1*08:02 and -DRB1*14:06, all 
associated with NMO risk in the present study, were in strong linkage disequilibrium (LD) with the rs9272219 
“A” risk allele. On the other hand, no NMO risk alleles, and two alleles associated with decreased NMO risk 
(-DQB1*03:02 and -DRB1*04:07) were in strong LD with the rs9272219 “C” allele.
Table 1.  Association statistics for genome-wide significant SNPs. RA, Risk allele. RAF: Risk allele frequency; 
UTS/ACP data set correspond to data obtained from Estrada et al.  201816.





Unconditioned Conditioned on rs9272219 UTS/ACP data set
OR (95% CI) P OR (95% CI) P OR P
rs9368726 32,438,542 HLA-DRB9 A 0.80 0.61 2.70 (1.92–3.70) 1 × 10–8 1.75 (1.09–2.86) 0.022 2.22 8 × 10–9
rs9405108 32,438,648 HLA-DRB9 G 0.80 0.61 2.70 (1.92–3.85) 8 × 10–9 1.75 (1.08–2.86) 0.023 2.22 8 × 10–9
rs1964995 32,449,411 Intergenic A 0.78 0.56 2.63 (1.92–3.70) 5 × 10–9 1.79 (1.09–2.94) 0.023 – –
rs9271588 32,590,953 Intergenic A 0.75 0.53 2.63 (1.92–3.57) 2 × 10–9 1.75 (1.05–2.86) 0.032 1.96 1 × 10–9
rs9272219 32,602,269 HLA-DQA1 A 0.67 0.42 2.48 (1.86–3.32) 8 × 10–10 – – – –
rs9273012 32,611,641 HLA-DQA1 G 0.67 0.42 2.49 (1.86–3.32) 8 × 10–10 – – – –
Table 2.  Comparison of HLA class I and class II allele frequencies in NMO patients and controls. AF, Allele 
frequency. Only alleles with a frequency ≥ 0.01 in both groups and with significant differences between cases 






PAF n AF n
Protective
B*39:05 0.0423 6 0.0979 19 0.04088
DRB1*07:01 0.0282 4 0.0876 17 0.01996
DRB1*04:07 0.0775 11 0.1598 31 0.01692
DQB1*02:02 0.0282 4 0.0979 19 0.00899
DQB1*03:02 0.1197 17 0.2887 56 0.00013
Risk
B*39:06 0.0775 11 0.0309 6 0.04818
B*35:14 0.0493 7 0.0103 2 0.03275
DQB1*04:02 0.2746 39 0.1546 30 0.00552
DRB1*14:06 0.0915 13 0.0206 4 0.00368
DRB1*16:02 0.1549 22 0.0515 10 0.00140
DRB1*08:02 0.2676 38 0.1289 25 0.00110
DQB1*03:01 0.3380 48 0.1546 30 0.00008
Table 3.  Comparison of HLA class I and class II haplotype frequencies in NMO patients and controls. HF, 
Haplotype frequency. Only haplotypes with a frequency ≥ 0.01 in both groups and with significant differences 
between cases and controls are presented.
HLA Haplotype
NMO (n = 71) Controls (n = 97)
PHF n Δ′ HF n Δ′
Protective
B*39:05-C*07:02 0.0423 6 1 0.0979 19 1 0.04088
DRB1*04:07-DQB1*03:02 0.0704 10 0.8967 0.1546 30 1 0.01300
DRB1*07:01-DQB1*02:02 0.0211 3 0.7428 0.0876 17 1 0.00796
Risk
B*35:14-C*04:01 0.0493 7 1 0.0103 2 1 0.03275
B*39:06-C*07:02 0.0704 10 0.8805 0.0206 4 1 0.02422
DRB1*14:06-DQB1*03:01 0.0915 13 1 0.0206 4 1 0.00368
DRB1*08:02-DQB1*04:02 0.2606 37 0.9637 0.1289 25 1 0.00177
DRB1*16:02-DQB1*03:01 0.1549 22 1 0.0515 10 1 0.00140
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We then used RFMix to infer the local ancestry (NAT, EUR or AFR) of all alleles described in Table 4, in both 
cases and controls. Notably, all NMO risk alleles HLA-DRB1*08:02, -DRB1*16:02 and -DRB1*14:06 were inferred 
to be of Native American ancestry, while risk alleles -DQB1*04:02 and -DQB1*03:01 were predominantly of NAT 
ancestry both in cases and controls. Regarding protective NMO alleles, -DRB1*04:07 and -DQB1*03:02 alleles 
were also predominantly of NAT ancestry(Fig. 3).
AQP4 sequencing. After sequencing all AQP4 exons including exon–intron boundaries, we identified 35 
SNPs in samples from NMO or MS Mexican patients. No novel variants were found. Thirteen of these variants 
were found in the 3′UTR region, one in the 5′UTR region, and three were synonymous variants. Although some 
variants were more frequent in NMO than in MS patients, the differences were not statistically significant. Sup-
plementary Table 10, compares the alternative allele frequency of these 35 SNPs in NMO and MS patients, 1,000 
Genomes continental populations and in 12 Native Mexican whole genome  sequences35.
Discussion
While several studies have stated that the epidemiology of NMO differs from that of MS, being more frequent 
in non-European  populations9–11, reliable comparisons among studies are difficult to establish. Epidemiological 
data suggest that ethnicity influences NMO prevalence, particularly in Latin  America10. In Mexico, there is only 
one non-population based study estimating NMO prevalence in a referral center located in Mexico  City12. To our 
knowledge, this is the first study in the Mexican admixed population where a genome-wide analysis revealed a 
higher proportion of Native American ancestry in NMO cases as compared to controls. This contrasts with the 
higher European genetic component previously observed in the Mexican patients with  MS36. The NAT ancestry 
estimated in our control group recruited in Mexico City (central Mexico) is consistent with previous NAT ances-
try estimations in the Mexican Mestizo population (~ 55%), known to gradually decline from South to North 
throughout the Mexican  territory37,38. Unfortunately, NMO epidemiological studies in Mexico are scarce, and 
there is no information on the geographical distribution or ethnicity of NMO patients in Mexico.
In our GWAS analysis, six SNPs within the MHC region were associated with NMO with genome-wide signifi-
cance. Both linkage disequilibrium and the conditional association analyses suggest that this association is driven 
by a single signal, led by two SNPs in perfect linkage disequilibrium (rs9272219 and rs9273012). There is only 
Table 4.  Comparison of HLA-DRB1 and HLA-DQB1 allele frequencies, stratified by rs9272219 genotype, 
in NMO patients and controls. AF, allele frequency. Only Alleles with a frequency ≥ 0.01 in both groups are 
presented.
rs9272219 HLA Allele
NMO (n = 31) Controls (n = 97)
PAF n Δ′ AF n Δ′
C
DQB1*04:02 0.0323 2 1 0.0155 3 1 NS
DRB1*04:04 0.0484 3 1 0.0619 12 0.8473 NS
DRB1*04:07 0.0484 3 1 0.1598 31 0.94 0.01528
DQB1*03:02 0.0968 6 1 0.2887 56 1 0.00107
DQB1*03:03 0.0161 1 1 0.0103 2 1 NS
DQB1*05:01 0.0323 2 1 0.0773 15 1 NS
DQB1*06:01 0.0161 1 1 0.0155 3 0.6337 NS
DQB1*06:02 0.0161 1 0.7338 0.0567 11 1 NS
DQB1*06:04 0.0161 1 1 0.0309 6 1 NS
DRB1*01:01 0.0161 1 1 0.0206 4 1 NS
DRB1*01:02 0.0161 1 1 0.0258 5 1 NS
DRB1*07:01 0.0161 1 1 0.0876 17 1 0.04056
DRB1*13:02 0.0161 1 1 0.0361 7 1 NS
DRB1*15:01 0.0161 1 0.7338 0.0567 11 1 NS
DRB1*15:02 0.0161 1 1 0.0206 4 1 NS
A
DQB1*04:02 0.2742 17 1 0.1392 27 1 0.01415
DRB1*03:01 0.0806 5 1 0.0412 8 1 NS
DRB1*08:02 0.2903 18 1 0.1237 24 1 0.00279
DRB1*14:02 0.0161 1 1 0.0309 6 1 NS
DRB1*16:02 0.1613 10 1 0.0515 10 1 0.00831
DQB1*03:01 0.3065 19 0.911 0.1546 30 1 0.00851
DQB1*02:01 0.0806 5 0 0.0412 8 1 NS
DQB1*03:19 0.0484 3 1 0.0103 2 1 NS
DRB1*11:02 0.0323 2 1 0.0155 3 1 NS
DRB1*11:04 0.0161 1 1 0.0206 4 1 NS
DRB1*14:06 0.0968 6 0.7153 0.0206 4 1 0.01497
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Figure 3.  Local ancestry of HLA alleles. Proportion of HLA alleles described in Table 4 inferred as Native 
American (NAT), European (EUR) or African (AFR). Local ancestry was estimated using RFMIX using trio-
phased populations as reference.
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one previous report of a GWAS for NMO in individuals of European  ancestry16, where two independent signals 
in the same MHC region were significantly associated with NMO: rs28383224, which is 18.6 kb downstream 
and rs1150757, which is 573.1 kb downstream the lead SNP found in the present study (rs9272219). Although 
rs28383224 and rs1150757 genotypes were not available in our analysis, both NMO GWAS share data on 3 of 
the 6 SNPs associated with NMO in the Mexican cohort (rs9368726, rs9405108 and rs9271588). These 3 SNPs 
were also associated with increased NMO risk in the European cohort, although with slightly lower odds ratio 
values. It is important to point out that we found no SNPs in proximity of rs1150757 associated with NMO in 
the Mexican population.
Class II HLA alleles (HLA-DQB1*03:01, -DRB1*08:02, -DRB1*16:02, -DRB1*14:06 and -DQB1*04:02) and 
class II haplotypes (HLA-DRB1*16:02-DQB1*03:01, -DRB1*08:02-DQB1*04:02 and -DRB1*14:06-DQB1*03:01) 
showed the most significant associations with increased NMO risk in the present Mexican cohort, while HLA-
DQB1*03:02 and -DQB1*02:02 alleles were significantly associated with decreased NMO risk. The HLA-
DRB1*16:02 allele has also been associated with NMO in Southern Han Chinese and Japanese populations, and 
more recently in Southern  Brazilians21–23. A very recent meta-analysis showed that the HLA-DRB1*16:02 allele 
was strongly associated with autoimmune diseases predominantly mediated by  autoantibodies5. The frequency 
of this allele varies across the world but it is highest in Native populations of America (~ 39%), is also frequent in 
populations from Oceania (~ 28%) and South-East Asia (~ 28%), but is relatively low in Europe (~ 6%) and Africa 
(~ 4%)39. Furthermore, haplotype HLA-DRB1*16:02-DQB1*03:01 is very frequent in Native American popula-
tions from the Southern state of Oaxaca (Mixe, Mixtec and Zapotec) and Xavantes from Central Brazil, but is very 
rare in other continental  populations39–41. Recently, haplotype HLA-DRB1*16-DQB1*03:01 was also associated 
with Parry-Romberg syndrome, an autoimmune disease affecting the craniofacial nerve in Mexican  patients42.
The HLA-DRB1*03:01 allele has been consistently associated with NMO in European populations, and 
admixed populations with important contribution of the European gene pool (Brazilian mulatto, Afro-Caribbean 
and a small Mexican mestizo cohort)13–20. The frequency of HLA-DRB1*03:01 is as high as 20% in European, 
North African, Western Asian populations, but ranges from only 0 to 2% in Native Mexican  populations39. 
Although in the present study the frequency of this allele was two-fold higher in cases as compared to controls 
(7.04% vs 4.12%, Supplementary Table 4), the difference did not reach statistical significance probably due to 
low statistical power derived from the small sample and effect sizes. Inconsistencies are not uncommon in 
genetic association studies and show the complexity of the genetic ancestry contribution in admixed populations. 
Interestingly, in the European GWAS, the HLA-DRB1*03:01 allele was imputed and found to be associated with 
AQP4-IgG-seropositive NMO but not with AQP4-IgG-seronegative NMO, and showed a high correlation with 
rs1150757  (r2 = 0.7) but a poor correlation with rs28383224  (r2 = 0.2)16. In the present study, the HLA-DRB1*03:01 
allele was not associated with NMO, nor with any SNP in proximity of rs1150757.
HLA alleles previously associated with NMO in populations with European and/or Native American ances-
try (HLA-DRB1*03:0113–20, -DRB1*16:0221–23 and -DQB1*04:0213,24) were in strong LD with the rs9272219 “A” 
risk allele. In contrast, two alleles significantly associated with decreased NMO risk in the present study (HLA-
DRB1*04:07 and -DQB1*03:02) were in strong LD with the rs9272219 “C” allele. Whether the latter are in fact 
NMO protective alleles needs to be confirmed in independent cohorts. Moreover, no previously reported NMO 
risk alleles were found in individuals with the rs9272219 “C” allele.
Notably, local ancestry analyses revealed that all HLA alleles most associated with NMO risk and protection 
in the present study were predominantly inferred as of Native American ancestry. This is consistent with our 
finding of a higher proportion of NAT ancestry in NMO cases as compared to controls, and with epidemiologi-
cal data suggesting that NMO is more prevalent in non-European  populations9–11. To our knowledge there is 
only one previous study analyzing local ancestry of demyelinating diseases, where HLA alleles DRB1*16:02 and 
DRB1*14:02 were inferred as of Native American ancestry in  Hispanics43, also in consistency with our local 
ancestry findings. As expected, the well-known HLA-DRB1*03:01 NMO risk allele was predominantly inferred 
as of European ancestry. Altogether, our SNP and HLA analyses suggest that a group of HLA alleles predomi-
nantly of Native American ancestry are associated with NMO susceptibility in the admixed Mexican population.
A limited number of studies have analyzed the role of AQP4 variants in the pathogenesis of NMO in  USA29, 
 Chinese30–32,  Japanese33 and  Spanish34 populations, with inconclusive results. We sequenced AQP4 coding regions 
in Mexican patients with NMO and MS, however no novel or missense variants were identified. Interestingly, four 
3′UTR variants (rs7240333, rs14393, rs1058424 and rs3763043) were more frequent in NMO as compared to MS 
patients, although the differences were not significant. Two of these variants (rs1058424 and rs3763043) showed 
a weak but significant association with NMO in the Han Chinese  population31. The highest frequencies of these 
four 3′UTR polymorphisms have been found in Native Mexicans (29.2%, 79.2%, 50% and 79.2%, respectively)35.
Some limitations of the study must be pointed out. Firstly, because no medical information was obtained from 
the control group (CANDELA project participants from Mexico), misclassification bias could potentially affect 
the statistical power of the study. Controls lacking medical information have been previously used in other GWAS 
studies, as the effect on statistical power is expected to be modest unless the extent of this bias is  substantial44. 
In the present study, it is unlikely albeit possible, that a low number of control participants were affected with 
NMO or could eventually develop NMO in the future. However, because NMO prevalence is very low, this bias 
is expected to be small. In addition, because of the possibility of spurious associations, the novel HLA associa-
tions here identified should be interpreted with caution and be confirmed in further studies including Mexican 
and other Latin American populations.
To our knowledge, this is the first study to examine the genetic ancestry of NMO patients supporting the 
notion that Native American ancestry significantly contributes to Neuromyelitis optica susceptibility in the 
admixed Mexican population. This finding is consistent with differences in the prevalence of NMO in popula-
tions of Mexico and Latin America, and contrasts with the epidemiology and genetics of multiple  sclerosis36,45.
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Methods
Study population. A total of 164 Mexican NMO patients were included. NMO diagnosis was based on 
Wingerchuk criteria described in 2006 and revised in  201546,47. All NMO participants had DNA samples stored 
at the National Institute of Neurology and Neurosurgery “Manuel Velasco Suárez” (INNN) DNA bank. Only 
DNA samples meeting quality requirements were used to perform microarray genotyping, high-resolution HLA 
typing and/or AQP4 sequencing. From the 164 NMO patients, it was possible to perform microarray analysis in 
119, high-resolution typing of the HLA region in 71 and AQP4 sequencing in 48 cases. Only 25 cases were avail-
able for the three platforms and 31 have microarray and high-resolution HLA typing. Moreover, 1,208 individu-
als from the Consortium for the Analysis of the Diversity and Evolution of Latin America (CANDELA)48 were 
included as a control group for the genome-wide association analysis. AQP4 sequencing data were compared 
in 48 NMO cases and 48 MS Mexican patients. All MS patients were recruited at the INNN and fulfilled the 
McDonald criteria for MS  diagnosis49. A sample of 15 trios from central Native Mexican populations (Nahuas 
and Totonacs) were included as a Native American (NAT) reference panel for ancestry analyses. All experiments 
were performed in accordance with the relevant guidelines and regulations.
Informed consent was obtained from all participants, and the study was approved by the Ethics Committee 
of INNN for NMO and MS patients; Universidad Nacional Autónoma de México for CANDELA controls; and 
Instituto Nacional de Medicina Genómica (INMEGEN) for NAT trios.
Genotyping. Eighty-three NMO samples were genotyped using the Illumina HumanOmniExpress array 
(~ 700,000 SNPs) and 36 using Illumina expanded Multi-Ethnic Genome Array (~ 1,700,000 SNPs), at the 
INMEGEN. Controls had been previously genotyped on HumanOmniExpress array as part of the CANDELA 
Consortium  study48. One of the CANDELA-Mexico controls was also genotyped at INMEGEN for quality con-
trol purposes, and microarray data concordance was 99.8%.
High‑resolution typing of the HLA region. HLA class I (A, B and C) and class II (DRB1 and DQB1) 
genes were typed by direct sequencing (sequence-based typing,  SBT50) in a total of 71 NMO samples and 97 con-
trols. Genotypes were called using Applied Biosystems analysis software (Foster City, CA, USA) and the IMGT/
HLA database alignment  tool51. Ambiguities were resolved using previously validated group-specific sequencing 
primers (GSSP)50.
AQP4 sequencing. AQP4 coding and UTR regions were sequenced on a Illumina MiSeq system. Prim-
ers were designed manually to span the regions of interest. Quality control of raw sequences was conducted 
using  FastQC52 and the  Trimmomatic53 algorithm was used to remove adapter sequences and trim short and 
low-quality end-read sequences. By using  Bowtie254 and  SAMTools55, we cleaned the sequence reads and then 
aligned them to the human reference genome (hg19) and variant calling and annotations.
Statistical analysis. Genome-wide screening. Quality control (QC) of the genotype data was carried out 
in PLINK56. SNPs and individuals were removed from the analysis based on minor allele frequency < 5%, call 
rate < 95%, deviation from the Hardy–Weinberg equilibrium (HWE) at P < 1 × 10–5 and genotyping efficien-
cy < 90%. Pairwise identity by descent (IBD) estimates were used to identify related individuals. No discordant 
sex information was found. After quality control, the data set comprised the genotypes of 119 NMO patients and 
1,208 controls for 252,805 SNPs.
Ancestry analyses were carried out using ADMIXTURE57 assuming three parental populations: EUR and 
AFR from the 1,000 Genomes project, and NAT genotypes of unrelated individuals, i.e. only parents of the 
NAT trios were included. The total number of autosomal SNPs common to the five populations (NMO patients, 
CANDELA controls, EUR, AFR and NAT) was 197,323. For each individual, the proportion of European, Afri-
can and Native American ancestry was estimated at the genomic level. The significance of differences between 
ancestry proportions in NMO patients as compared to controls was determined using a T-test statistic. Local 
ancestry was determined through a random forest procedure using RFMix with 5 expectation–maximization 
(EM) iterations and a minimum of 6 reference haplotypes per tree  node58. EUR and AFR from 1,000 Genomes 
project, along with trio phased NAT genotypes were used as reference populations for local ancestry. Haplotype 
phasing of NAT, NMO and control subjects was performed with  Beagle59.
A genome-wide case–control association study was conducted using logistic regression models, adjusting for 
sex and two principal components, assuming an additive effect using PLINK56.
HLA region analysis. Allele and haplotype frequencies were obtained by direct counting, and haplotype blocks 
were built based on previous reports. Allele frequencies for HLA-A, -B, -C, -DRB1 and -DQB1 were compared 
between NMO patients and the control group. Maximum-likelihood haplotype frequencies for two-point, three-
point and four-point associations were estimated in each group using an EM algorithm implemented in Arle-
quin v3.160. Linkage disequilibrium (LD; Δ and Δ′) and HWE were also calculated using Arlequin. Class II HLA 
haplotype were stratified by SNP rs9272219 and the significance of the differences between NMO patients and 
CANDELA controls was determined using a Fisher’s exact test.
Data availability
The dataset for the NMO patients generated and/or analyzed during the current study are available from the 
corresponding authors on reasonable request. Access to the CANDELA dataset used in this manuscript was 
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